Furthermore, laboratory markers such as gamma-Glutamyltransferase (GGT) and alanine aminotransferase (ALT) have emerged as potential indicators of increased CIMT in MASH patients, highlighting the systemic nature of the disease and its impact on vascular health (Targher et al., 2006). This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.